Search alternatives:
decrease processes » disease processes (Expand search), decay processes (Expand search), increase process (Expand search)
decrease decrease » decrease release (Expand search), disease decreases (Expand search), decreases disease (Expand search)
response decrease » response defense (Expand search)
acuity response » acute response (Expand search), immunity response (Expand search), auditory response (Expand search)
decrease after » increase after (Expand search), disease after (Expand search)
decrease toc » decrease of (Expand search), decrease the (Expand search), decreased to (Expand search)
toc decrease » to decrease (Expand search), the decrease (Expand search), not decrease (Expand search)
decrease processes » disease processes (Expand search), decay processes (Expand search), increase process (Expand search)
decrease decrease » decrease release (Expand search), disease decreases (Expand search), decreases disease (Expand search)
response decrease » response defense (Expand search)
acuity response » acute response (Expand search), immunity response (Expand search), auditory response (Expand search)
decrease after » increase after (Expand search), disease after (Expand search)
decrease toc » decrease of (Expand search), decrease the (Expand search), decreased to (Expand search)
toc decrease » to decrease (Expand search), the decrease (Expand search), not decrease (Expand search)
1
2
3
4
5
“... OK treatment does not affect objectively measured the accommodative response of young, low myopic eyes after...”
Access document
Access document
Article
6
7
“... to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were...”
Access document (1)
Access document (2)
Access document (1)
Access document (2)
Article
8
“... to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were...”
Access document
Access document
Article
9
10
“... with worse visual acuity. Fifteen days after treatment patient reported better visual acuity on the...”
Access document
Access document
Article
11
12
13
14
15
16
17
18
“... functional and anatomical outcomes after monthly intravitreal bevacizumab for the treatment of macular edema...”
Access document
Access document
Article
19
20